2025年，在《广州南沙深化面向世界的粤港澳全面合作总体方案》（简称"《南沙方案》"）第一阶段目 标顺利达成之际，南沙作为立足湾区、协同港澳、面向世界的国家重大战略性平台，迎来三大国家级政 策红利加速全面释放。 《南沙意见》率先在生物医药和智能无人系统领域开展制度型开放探索。在细胞与基因治疗方面，《南 沙意见》允许经备案的企业依托医疗机构开展限制类细胞移植治疗技术临床应用，已实现全国首例地中 海贫血细胞与基因治疗、首例异体干细胞治疗肝衰竭等突破，多个干细胞治疗项目进入临床应用阶 段，"实验室—病床"转化效率显著提升。细胞与基因治疗从临床研究到病床前的距离，正在南沙大幅缩 短。2025年6月，全国首例地中海贫血细胞与基因治疗临床应用患者在南沙完成出舱，短短半年时间， 已有38名地贫患者顺利出院，跑出南沙细胞与基因治疗的"加速度"。 "南沙金融30条"从7个维度，全方位赋能南沙的开发与开放。"南沙金融30条"直指跨境融资 的"慢"与"难"。传统模式下，飞机或船舶的跨境融资，往往因审批层级多、资本金管制严而流程冗 长。"南沙金融30条"果断"拆墙"，落地广东省首单金融租赁公司外币直接借款（890万美元）及首笔融 资 ...

本届大会上，海医汇集中发布了10余项技术，覆盖血液与健康生态、细胞与基因治疗、高端科研仪器、 罕见病诊疗、脑重大疾病防治及AI+重大疾病防治等多个前沿领域。同时，海医汇携手生态伙伴于本届 大会上发起"汇聚AI智慧，促进医疗共融共创新范式"倡议，旨在以AI技术驱动科研范式变革，共同推动 AI技术在医疗健康领域的深度融合与转化应用，加速科技创新成果从实验室走向临床普惠。 此外，海尔盈康一生与首都医科大学再度携手，于本届大会上启动"科创菁英培育计划"二期，将进一步 拓展合作广度与培育深度，共同搭建贯通"基础-临床-转化"的协同培育体系，助力更多青年科研人才 将"想法"转化为"成果"。 12月19日，以"Al for Health·助力健康中国2030"为主题的第二届海医汇医疗科技创新生态大会在北京召 开。本届大会由中国研究型医院学会、中国医学科学院北京协和医学院、广州实验室主办，海医汇承 办，北京脑重大疾病研究院为支持单位，《医师报》社为战略支持媒体。大会汇聚知名院士、专家学者 及行业领军企业代表，共同探讨在AI与科技驱动下，跨越从基础研究到产业应用的"达尔文之海"，构建 科研与产业协同新范式，为医疗健康领域新质生 ...

Core Insights - The joint policy from three ministries in January 2024 has significantly accelerated the development of the cell and gene therapy industry in Nansha, allowing clinical applications of restricted cell transplantation technologies under certain conditions [1][3] - The establishment of three major public service centers in Nansha aims to enhance the infrastructure for cell and gene therapy, focusing on clinical application, safety evaluation, and data management [1][4] Group 1: Infrastructure Development - The Guangdong Jihe Stem Cell Engineering Co., Ltd. is leading the construction of a clinical-grade seed cell bank in Nansha with a total planned investment of 200 million yuan, which will facilitate the research and clinical transformation of cell technology [3][4] - The public service center in Nansha will serve as a national-level platform integrating high-precision quality testing, intelligent sample storage, and comprehensive data management for cell therapy [9][10] Group 2: Evaluation and Safety - The establishment of the Bay Area Biological Therapy Health Effect Evaluation Center aims to create an internationally leading evaluation system for the safety, effectiveness, and health effects of biological therapies, addressing key challenges in clinical translation [5][6] - The center will focus on four core areas: multi-dimensional efficacy evaluation of cell therapies, research on side effects, precise immune assessment, and biological age prediction for health intervention [6][7] Group 3: Industry Collaboration and Growth - Nansha is positioned to leverage its geographical advantages and resources from the Greater Bay Area to build a global innovation hub for biological therapy, attracting industry experts and fostering collaboration among over 400 biopharmaceutical companies [12][13] - The integration of data accumulation and AI technology is expected to enhance treatment efficacy and optimize patient care in the field of biological therapy [13]